1. Home
  2. HEQ vs ELDN Comparison

HEQ vs ELDN Comparison

Compare HEQ & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Hancock Hedged Equity & Income Fund of Beneficial Interest

HEQ

John Hancock Hedged Equity & Income Fund of Beneficial Interest

HOLD

Current Price

$10.98

Market Cap

133.9M

Sector

Finance

ML Signal

HOLD

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

HOLD

Current Price

$2.03

Market Cap

123.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HEQ
ELDN
Founded
2011
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
133.9M
123.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HEQ
ELDN
Price
$10.98
$2.03
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
43.1K
891.4K
Earning Date
01-01-0001
11-14-2025
Dividend Yield
9.78%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.08
$1.35
52 Week High
$11.84
$4.97

Technical Indicators

Market Signals
Indicator
HEQ
ELDN
Relative Strength Index (RSI) 62.00 66.58
Support Level $10.77 $1.70
Resistance Level $10.88 $1.76
Average True Range (ATR) 0.11 0.11
MACD 0.03 0.07
Stochastic Oscillator 69.14 95.90

Price Performance

Historical Comparison
HEQ
ELDN

About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest

John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Share on Social Networks: